vs
ICU MEDICAL INC（ICUI）与Zscaler, Inc.（ZS）财务数据对比。点击上方公司名可切换其他公司
Zscaler, Inc.的季度营收约是ICU MEDICAL INC的1.5倍（$788.1M vs $540.7M），Zscaler, Inc.净利率更高（-1.5% vs -2.9%，领先1.4%），Zscaler, Inc.同比增速更快（25.5% vs -14.1%），Zscaler, Inc.自由现金流更多（$431.0M vs $36.0M），过去两年Zscaler, Inc.的营收复合增速更高（22.5% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
Zscaler是总部位于美国加利福尼亚州圣何塞的云安全企业，专注提供云原生安全服务，为全球各行业企业的网络系统与数据资产提供全方位防护，助力企业在数字化运营过程中抵御各类安全风险，保障业务稳定开展。
ICUI vs ZS — 直观对比
营收规模更大
ZS
是对方的1.5倍
$540.7M
营收增速更快
ZS
高出39.7%
-14.1%
净利率更高
ZS
高出1.4%
-2.9%
自由现金流更多
ZS
多$395.0M
$36.0M
两年增速更快
ZS
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q1 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $788.1M |
| 净利润 | $-15.7M | $-11.6M |
| 毛利率 | 37.5% | 76.6% |
| 营业利润率 | 1.0% | -4.6% |
| 净利率 | -2.9% | -1.5% |
| 营收同比 | -14.1% | 25.5% |
| 净利润同比 | 34.0% | 3.6% |
| 每股收益（稀释后） | $-0.63 | $-0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIZS
| Q4 25 | $540.7M | $788.1M | ||
| Q3 25 | $537.0M | $719.2M | ||
| Q2 25 | $548.9M | $678.0M | ||
| Q1 25 | $604.7M | $647.9M | ||
| Q4 24 | $629.8M | $628.0M | ||
| Q3 24 | $589.1M | $592.9M | ||
| Q2 24 | $596.5M | $553.2M | ||
| Q1 24 | $566.7M | $525.0M |
净利润ICUIZS
| Q4 25 | $-15.7M | $-11.6M | ||
| Q3 25 | $-3.4M | $-17.6M | ||
| Q2 25 | $35.3M | $-4.1M | ||
| Q1 25 | $-15.5M | $-7.7M | ||
| Q4 24 | $-23.8M | $-12.1M | ||
| Q3 24 | $-33.0M | $-14.9M | ||
| Q2 24 | $-21.4M | $19.1M | ||
| Q1 24 | $-39.5M | $-28.5M |
毛利率ICUIZS
| Q4 25 | 37.5% | 76.6% | ||
| Q3 25 | 37.4% | 76.1% | ||
| Q2 25 | 37.9% | 77.0% | ||
| Q1 25 | 34.7% | 77.1% | ||
| Q4 24 | 36.1% | 77.5% | ||
| Q3 24 | 34.8% | 78.0% | ||
| Q2 24 | 34.8% | 78.6% | ||
| Q1 24 | 32.7% | 77.7% |
营业利润率ICUIZS
| Q4 25 | 1.0% | -4.6% | ||
| Q3 25 | 2.6% | -4.5% | ||
| Q2 25 | 1.9% | -3.7% | ||
| Q1 25 | 2.1% | -6.2% | ||
| Q4 24 | 6.0% | -4.9% | ||
| Q3 24 | 1.4% | -4.5% | ||
| Q2 24 | 1.3% | -0.5% | ||
| Q1 24 | -1.9% | -8.7% |
净利率ICUIZS
| Q4 25 | -2.9% | -1.5% | ||
| Q3 25 | -0.6% | -2.4% | ||
| Q2 25 | 6.4% | -0.6% | ||
| Q1 25 | -2.6% | -1.2% | ||
| Q4 24 | -3.8% | -1.9% | ||
| Q3 24 | -5.6% | -2.5% | ||
| Q2 24 | -3.6% | 3.5% | ||
| Q1 24 | -7.0% | -5.4% |
每股收益（稀释后）ICUIZS
| Q4 25 | $-0.63 | $-0.07 | ||
| Q3 25 | $-0.14 | $-0.11 | ||
| Q2 25 | $1.43 | $-0.03 | ||
| Q1 25 | $-0.63 | $-0.05 | ||
| Q4 24 | $-0.97 | $-0.08 | ||
| Q3 24 | $-1.35 | $-0.09 | ||
| Q2 24 | $-0.88 | $0.12 | ||
| Q1 24 | $-1.63 | $-0.19 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.3B |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $2.0B |
| 总资产 | $4.1B | $6.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIZS
| Q4 25 | — | $1.3B | ||
| Q3 25 | — | $2.4B | ||
| Q2 25 | — | $2.0B | ||
| Q1 25 | — | $1.8B | ||
| Q4 24 | $308.6M | $1.6B | ||
| Q3 24 | $312.5M | $1.4B | ||
| Q2 24 | $302.6M | $1.3B | ||
| Q1 24 | $251.4M | $1.4B |
总债务ICUIZS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $1.1B | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | — | $1.1B | ||
| Q1 24 | — | $1.1B |
股东权益ICUIZS
| Q4 25 | $2.1B | $2.0B | ||
| Q3 25 | $2.1B | $1.8B | ||
| Q2 25 | $2.1B | $1.8B | ||
| Q1 25 | $2.0B | $1.6B | ||
| Q4 24 | $2.0B | $1.4B | ||
| Q3 24 | $2.0B | $1.3B | ||
| Q2 24 | $2.0B | $1.1B | ||
| Q1 24 | $2.1B | $958.9M |
总资产ICUIZS
| Q4 25 | $4.1B | $6.5B | ||
| Q3 25 | $4.1B | $6.4B | ||
| Q2 25 | $4.1B | $5.3B | ||
| Q1 25 | $4.2B | $5.0B | ||
| Q4 24 | $4.2B | $4.7B | ||
| Q3 24 | $4.3B | $4.7B | ||
| Q2 24 | $4.3B | $4.2B | ||
| Q1 24 | $4.3B | $3.9B |
负债/权益比ICUIZS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.64× | ||
| Q1 25 | — | 0.71× | ||
| Q4 24 | — | 0.80× | ||
| Q3 24 | — | 0.90× | ||
| Q2 24 | — | 1.04× | ||
| Q1 24 | — | 1.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $448.3M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $431.0M |
| 自由现金流率自由现金流/营收 | 6.6% | 54.7% |
| 资本支出强度资本支出/营收 | 4.6% | 2.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $924.9M |
8季度趋势，按日历期对齐
经营现金流ICUIZS
| Q4 25 | $60.6M | $448.3M | ||
| Q3 25 | $56.7M | $250.6M | ||
| Q2 25 | $11.2M | $211.1M | ||
| Q1 25 | $51.3M | $179.4M | ||
| Q4 24 | $40.2M | $331.3M | ||
| Q3 24 | $36.1M | $203.6M | ||
| Q2 24 | $82.0M | $173.4M | ||
| Q1 24 | $45.8M | $142.1M |
自由现金流ICUIZS
| Q4 25 | $36.0M | $431.0M | ||
| Q3 25 | $27.6M | $190.6M | ||
| Q2 25 | $-8.5M | $138.9M | ||
| Q1 25 | $36.7M | $164.4M | ||
| Q4 24 | $16.1M | $314.3M | ||
| Q3 24 | $16.2M | $154.2M | ||
| Q2 24 | $62.5M | $137.8M | ||
| Q1 24 | $29.9M | $111.2M |
自由现金流率ICUIZS
| Q4 25 | 6.6% | 54.7% | ||
| Q3 25 | 5.1% | 26.5% | ||
| Q2 25 | -1.5% | 20.5% | ||
| Q1 25 | 6.1% | 25.4% | ||
| Q4 24 | 2.6% | 50.1% | ||
| Q3 24 | 2.7% | 26.0% | ||
| Q2 24 | 10.5% | 24.9% | ||
| Q1 24 | 5.3% | 21.2% |
资本支出强度ICUIZS
| Q4 25 | 4.6% | 2.2% | ||
| Q3 25 | 5.4% | 8.3% | ||
| Q2 25 | 3.6% | 10.6% | ||
| Q1 25 | 2.4% | 2.3% | ||
| Q4 24 | 3.8% | 2.7% | ||
| Q3 24 | 3.4% | 8.3% | ||
| Q2 24 | 3.3% | 6.4% | ||
| Q1 24 | 2.8% | 5.9% |
现金转化率ICUIZS
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.32× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 9.07× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
ZS
暂无分部数据
